All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies, February 24–27 2019, Munich, DE
The Alfred Hospital, Victoria, AU
Targeting cell survival in AML
Venetoclax in combination with hypomethylating agents for the treatment of older patients with NPM1-mutated acute myeloid leukemia
Approximately 30% of patients with acute myeloid leukemia (AML) have nucleophosmin-1 mutations (NPM1+), which are...
Venetoclax plus 10-day decitabine in chemotherapy-ineligible patients with newly diagnosed or R/R AML
The prognosis of acute myeloid leukemia (AML) in older patients is usually poor, due to the presence of comorbidities and the early mortality...
Subscribe to get the best content related to AML delivered to your inbox